Recomposition with IGF-1 LR3: realistic expectations

Recomposition with IGF-1 LR3 is the most-asked, least-understood use case for the most-direct anabolic peptide in the strength category. The hope is simultaneous muscle gain and fat loss. The biology is more constrained than that hope. IGF-1 LR3 supports muscle protein synthesis directly, but it does not flip energy balance — and energy balance is what determines whether body fat is moving up or down. This guide is the honest read on what IGF-1 LR3 contributes to a recomp, what it does not, and how to structure a cycle around realistic expectations.

What "recomposition" actually means

Body recomposition is simultaneous reduction in body-fat percentage and increase in lean mass. It happens, but the conditions are narrow:

Outside those conditions, recomp gets slow and small. A lifter with 5+ years of training, low body fat, and consistent eating will not see dramatic simultaneous gain and loss regardless of peptide stack.

Where IGF-1 LR3 fits

IGF-1 LR3 binds the IGF-1 receptor and activates the same anabolic signaling that endogenous IGF-1 does — except with longer half-life, less binding-protein sequestration, and higher receptor potency. The downstream effect:

• Increased muscle protein synthesis
• Enhanced amino acid uptake
• Mild insulin-like effect on glucose uptake
• Modest hyperplasia signaling in muscle tissue

What it does not do:

• Drive fat loss directly. There is no lipolytic mechanism comparable to GH.
• Flip energy balance. In a surplus, IGF-1 LR3 helps build muscle. In a deficit, it helps preserve muscle and supports synthesis where substrate is available.
• Replace training. The signaling needs a stimulus to attach to.

For the comparison with GH peptides, see IGF-1 LR3 vs GH secretagogues.

Realistic recomp scenarios on IGF-1 LR3

The middle row is where most users sit and where IGF-1 LR3 over-promises. The signaling is real; the body composition shift is small over a 4–6 week cycle.

Dose ranges and cycle structure

IGF-1 LR3 is dosed in micrograms — much smaller than other strength peptides:

Above 80 mcg/day, side effects rise sharply (hypoglycemia, numbness, headaches) and benefits do not reliably scale. Cycles run 4–6 weeks. Receptor desensitization and cancer-axis caveats argue against longer.

For the protocol detail, see IGF-1 LR3 protocol and IGF-1 LR3 cycle length.

Stacking IGF-1 LR3 for recomp

The most-defensible recomp stack:

What to avoid:

• IGF-1 LR3 alone with no GH-axis support (feedback suppression of natural GH)
• IGF-1 LR3 + synthetic HGH (compounded risk on the same axis)
• IGF-1 LR3 + MK-677 in a deficit (insulin sensitivity drift)

See IGF-1 LR3 with GH peptides.

The diet question — small deficit, maintenance, or small surplus

Recomp diet structure with IGF-1 LR3 is calibrated to body fat starting point:

Protein stays high regardless: 0.8–1g per lb bodyweight. Carbohydrate timing around training matters more than total carb intake for recomp on IGF-1 LR3.

Hypoglycemia, training, and meal timing

IGF-1 LR3 has insulin-like effects. Blood glucose can drop, particularly when:

• Injecting on an empty stomach
• Pre-workout dose followed by long training session without intra-workout fuel
• Stacking with insulin or insulin-sensitizing supplements
• Low-carb cuts

Most users eat a meal 30–60 minutes before injecting and keep a quick-carb source available. Training-day timing usually puts one dose post-workout (with the meal) and the optional second dose around the second largest meal of the day.

For the side-effect detail, see IGF-1 LR3 protocol.

What recomp actually looks like

A realistic 6-week IGF-1 LR3 cycle on a recomp setup (trained lifter, 16% body fat, maintenance calories, 1g protein per lb):

• 1–3 lb lean mass gain
• 0.5–1.5% body fat reduction
• Strength gains modest, attached more to programming than to peptide
• Better recovery and pump quality during sessions
• Visible upper-body composition shift more than lower-body

Anyone selling 8+ lb lean gain with simultaneous 3%+ body fat drop in a 6-week cycle is selling marketing. The biology does not support that scale of change in trained lifters.

Cancer-axis caveats — non-negotiable

IGF-1 is a documented growth factor implicated in proliferation pathways. Position IGF-1 LR3 carefully:

• Active or recent cancer: absolute contraindication
• Strong family history of hormone-sensitive cancer: discuss with a clinician before considering
• Any history of malignancy: caution, even if remote
• No cancer history: theoretical risk at 4–6 week cycles, not measured — proceed informed and with bloodwork

This is the strongest reason to keep IGF-1 LR3 cycles short and infrequent. See the IGF-1 LR3 pillar guide for the deeper version.

Bloodwork before and after

Minimum useful panel for an IGF-1 LR3 cycle:

• Fasting glucose, A1C
• IGF-1
• Lipid panel
• Comprehensive metabolic
• PSA in men over 40
• CBC

End-of-cycle bloodwork is more informative than mid-cycle — it shows recovery to baseline. See peptides and bloodwork.

When IGF-1 LR3 is not the right tool

Skip IGF-1 LR3 if:

• This is your first peptide cycle (run a recovery peptide or GH secretagogue first)
• You are in a deep deficit (signaling without substrate)
• You have not run baseline labs
• You have any active or recent cancer concern, or strong family history
• You are pre-diabetic or have insulin sensitivity issues
• Budget cannot also cover good vendor quality and bloodwork

A GH secretagogue stack does most of what IGF-1 LR3 does for recomp, more gently and with a more forgiving risk profile. Many users never need the IGF-1 LR3 layer.

Related reading

• IGF-1 LR3 complete guide
• IGF-1 LR3 vs GH secretagogues
• IGF-1 LR3 cycle length
• GH secretagogues for fat loss
• Peptides and bloodwork